Director Appointment
Released
Released
Announcement PDF
ASX Release
28 February 2018
Appointment of Director & Appendix 3X
Resonance Health (ASX: RHT) advises that it has appointed Mr. Mitchell Wells as a Non-Executive Director of
the Company.
Mr. Wells replaces Dr. Jason Loveridge who resigned as a Non-Executive Director of the Company on 30 June
2017 to take up a senior position at a pharmaceutical company.
Mr. Wells is an experienced senior executive and a qualified lawyer with commercial and legal experience in
Australia, the United States of America and the United Kingdom.
He has served as a director and worked as a senior executive of listed-public and private companies including
ASX and Nasdaq listed companies. He currently serves as Chair of two not-for-profit organisations.
Since May 2017 Mr. Wells has provided corporate, legal and investor-relations consulting services to the
Company and he will continue to consult to the Company for one to two days per week, or as required by
the Company.
Dr. Martin Blake, Chairman of the Board, commented: “Mr. Wells is commercially focused and has played a
key role in the corporate restructuring of the Company over the past 9 months and its re-energised focus
on commercial and shareholder-return outcomes. He has a strong governance background and a thorough
understanding of listed companies and his corporate and legal background will further diversify the skillsets
represented on our Board. The Board looks forward to continuing its work with him and to his increased
involvement in the Company.”
Enclosed is Mr. Wells’ Appendix 3X - Initial Director’s Interest Notice.
Martin Blake
Chairman RHT
For further information please contact:
Alison Laws
Chief Executive Officer, Resonance Health
E: alisonl@resonancehealth.com P: +61 (0)8 9286 5300
Resonance Health Ltd. ABN: 96 006 762 492
141 Burswood Road, Burswood, WA 6100, AUSTRALIA
Postal: PO Box 71, Burswood, WA, 6100, AUSTRALIA
www.resonancehealth.com
T + 61 8 9286 5300
info@resonancehealth.com
Appendix 3X
Initial Director’s Interest Notice
Rule 3.19A.1
Appendix 3X
Initial Director’s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and
documents given to ASX become ASX’s property and may be made public.
Introduced 30/9/2001.
Name of entity
ABN
Resonance Health Limited
96 006 762 92
We (the entity) give ASX the following information under listing rule 3.19A.1 and as
agent for the director for the purposes of section 205G of the Corporations Act.
Name of Director
Mitchell Wells
Date of appointment
28th February 2018
Part 1 - Director’s relevant interests in securities of which the director is the registered holder
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should
be disclosed in this part.
Number & class of securities
Nil holdings in the Company.
+ See chapter 19 for defined terms.
11/3/2002
Appendix 3X Page 1
Appendix 3X
Initial Director’s Interest Notice
Part 2 – Director’s relevant interests in securities of which the director is not the registered
holder
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Name of holder & nature of interest
Number & class of Securities
None
Nil holdings in the Company.
Note: Provide details of the circumstances giving
rise to the relevant interest.
Part 3 – Director’s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should
be disclosed in this part.
Detail of contract
Nil
Nature of interest
Name of registered holder
(if issued securities)
No. and class of securities to which
interest relates
+ See chapter 19 for defined terms.
Appendix 3X Page 2
11/3/2002
Share your feedback
Discover